Skip to main content

Table 1 Patient characteristics at baseline and follow-up

From: IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment

  Baseline Follow-up p-value
Creatinine, μmol/l, median 82 (52–284) 77 (48–306) ns
Proteinuria, g/d, median 1.45 (0–8.4) 0.5 (0–3.6) <0.001
C3, g/l, median 0.5 (0.12-1.13) 0.74 (0.36-1.41) <0.001
C4, g/l, median 0.11 (0.02-0.51) 0.13 (0.02-0.45) 0.002
Anti-DNA-ab positivity # , % 84 57  
Nephritis class, WHO (n)    
I-II - 19  
III 15 9  
III/V 4 1  
IV 24 8  
V 8 14  
Vasculits 1 1  
Activity index, median 5 (0–13) 2 (0–12) <0.001
Chronicity index, median 1 (0–6) 1 (0–8) <0.001
Treatment (n)    
Cyclophosphamide 40   
Mycophenolate mofetil 9   
Rituximab 2   
Azathioprin 1   
Prednisolone dose, median 40 (2.5-80) 10 (2.5-30)  
BILAG , renal    
A 49 8  
B 3 20  
C   12  
D   12  
  1. Range are given in parenthesis, #Anti-dsDNA raised to at least 1:25, BILAG, British Isles Lupus Assessment Group.